Skip to main content

Table 2 Outcomes of the allopurinol group and comparisons on the use of diuretics

From: Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort

  No diuretics
(n = 142 (68.3%))
Diuretics
(n = 66 (31.7%))
P
Primary outcome variable
 Maximum dose of allopurinol (mg/day) 304.9 (120.6) 275.8 (119.7) 0.109
Secondary outcome variables
 Baseline SU (mg/dL) 8.1 (1.4) 8.4 (1.6) 0.116
 Final SU (mg/dL) 4.9 (1.3) 5.4 (1.7) 0.015
 Final eGFR (mL/min) 83.0 (24.4) 64.6 (21.5) < 0.001
 SU reduction (mg/dL) 3.2 (1.8) 3.0 (1.9) 0.474
 Achievement of SU targets
  - SU <6 mg/dL, n (%) 110 (79.1) 47 (68.1) 0.082
  - SU <5 mg/dL, n (%) 75 (54.0) 27 (39.1) 0.044
  - SU <4 mg/dL, n (%) 34 (24.5) 11 (15.9) 0.160
  1. Data shown as mean (SD) unless specified otherwise. In bold, statistically significant differences between subgroups. eGFR estimated glomerular filtration rate, SD standard deviation, SU serum urate